$ 1,580.0
Quantity: 5 MG
In stock
Description
Product name: LTX-109
Catalog#: 1304005
Organism:
Synonyms:
CAS NO.:
Sequence: Arg-Tbt-Arg-NH-CH2CH2-C5H5
Modifications:
M.W: 684.92
M.F.: C35H60N10O4
Purity: 95% by HPLC
Counter ion: Trifluoacetate
Format: Lyophilized powder
Description: Lytix Biopharma is developing LTX-109(Arg-Tbt-Arg-NH-CH2CH2-C5H5), a first-in-class chemically synthesized, peptide-mimetic drug that is stable against protease degradation and represents a new approach to the serious challenge of S. aureus nasal decolonization. LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug that binds to negatively charged membrane components on the bacterial cell, which is followed by membrane disruption and cell lysis. Nonclinical and clinical studies have demonstrated that topical application of LTX-109 (1 to 5%) has a good safety profile and a low bioavailability. LTX-109 shows significant in vitro bactericidal activity against a variety of S. aureus strains with LTX-109 MIC values of 0.03 to 8 mg/liter and isolates resistant to several classes of antimicrobial agents, including mupirocin-resistant strains. In addition, LTX-109 has demonstrated activity against bacterial and fungal biofilms. Due to its novel mechanism of action, there is a very low propensity for resistance development compared to that of conventional antibiotics.
Uniprot ID:
Usage: For Scientific Research Use Only, Not for Human Use.
